SCHEMBL14133539

SCHEMBL14133539

CCS(=O)(=O)Nc1ccc(C2=NN(C(C)=O)C(c3cccc(F)c3)C2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.75
▸ PKM P14618 7/20 0.75
▸ KDM4E B2RXH2 7/20 0.75
▸ MAPT P10636 2/20 0.75
▸ GLA P06280 3/20 0.66
▸ GAA P10253 2/20 0.66
▸ CA1 P00915 3/20 0.58
▸ CA2 P00918 3/20 0.58
▸ CA9 Q16790 3/20 0.58
▸ CA4 P22748 1/20 0.58
▸ NT5E P21589 1/20 0.58
▸ HTT P42858 3/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ MAOA P21397 2/20 0.54
▸ MAOB P27338 2/20 0.54
▸ KIF11 P52732 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14133355 0.91 KDM4E (0.74) ALDH1A1PKMKDM4EMAPTGLA
SCHEMBL14133395 0.90 ALDH1A1 (0.74) ALDH1A1PKMKDM4EMAPTGLA
SCHEMBL14133904 0.88 PTGS2 (0.69) ALDH1A1PKMKDM4EMAPTGLA
SCHEMBL14133779 0.88 ALDH1A1 (0.73) ALDH1A1PKMKDM4EMAPTGLA
SCHEMBL14133533 0.86 KDM4E (0.71) ALDH1A1PKMKDM4EMAPTGLA
SCHEMBL14133536 0.86 PKM (1.00) ALDH1A1PKMKDM4EMAPTGLA
SCHEMBL14133805 0.84 KDM4E (0.71) ALDH1A1PKMKDM4EMAPTGLA
SCHEMBL14133630 0.83 KDM4E (0.83) ALDH1A1PKMKDM4EMAPTGLA
SCHEMBL14133534 0.82 PKM (0.68) ALDH1A1PKMKDM4EMAPTGLA
SCHEMBL14133743 0.81 KDM4E (0.80) ALDH1A1PKMKDM4EMAPTGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 ALDH1A1 2476/4885PKM 5/4885KDM4E 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback